Ann: Imugene Investor Webinar - MAST Study Update, page-188

Hi Rigo,
I see it a little in the vein of dance partners, goose in the window etc. Surprised it hasn’t gotten more flak from others, given the disgruntlement shown towards the other comments.
For this question in particular some more information could have been provided, ie hypothetically we would need x/y/z data points before applying (after 10 bile ducts patients or before probably key question I’m wondering).

Stay tuned gives nothing useful, with another question - they’ve said Phase 2/3 for changing SoC, I bet they are hoping to do it earlier with some very compelling data (adding in CF33 as later line of therapy initially) but they’ve laid out the likely info for us.

I think stay tuned seems like they are on the edge or are already doing it. Whereas it could require data from expansion which could be received Q1-Q2 of 2025.